HSDT
Solana Company
Medical - Devices
Market Cap$87M
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HSDT vs MBOT
Revenue, margins, valuation, and 5-year total return — side by side.
MBOT
Microbot Medical Inc.
Medical - Instruments & Supplies
Market Cap$143M
5Y Perf.-71.8%
HSDT vs MBOT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HSDT | MBOT |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $87M | $143M |
| Revenue (TTM) | $6M | $0.00 |
| Net Income (TTM) | $-41M | $-13M |
| Gross Margin | 91.7% | — |
| Operating Margin | -351.0% | — |
| Total Debt | $0.00 | $111K |
| Cash & Equiv. | $7M | $3M |
HSDT vs MBOT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HSDT
MBOT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Solana Company (HSDT) | 100 | 0.0 | -100.0% |
| Microbot Medical In… (MBOT) | 100 | 28.2 | -71.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HSDT vs MBOT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MBOT leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Solana Company is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
HSDT
Solana Company
The Growth Play
HSDT is the clearest fit if your priority is growth exposure.
- Rev growth 10.6%, EPS growth 57.3%, 3Y rev CAGR 97.0%
- 10.6% revenue growth vs MBOT's -17.1%
- -20.7% ROA vs MBOT's -34.4%, ROIC -10.8% vs -6.2%
Best for: growth exposure
MBOT
Microbot Medical Inc.
The Income Pick
MBOT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 1.85
- -99.4% 10Y total return vs HSDT's -100.0%
- Lower volatility, beta 1.85, Low D/E 3.1%, current ratio 2.37x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | HSDT | 10.6% revenue growth vs MBOT's -17.1% |
| Quality / Margins | MBOT | 3.0% margin vs HSDT's -6.8% |
| Stability / Safety | MBOT | Beta 1.85 vs HSDT's 2.77 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MBOT | -15.1% vs HSDT's -99.0% |
| Efficiency (ROA) | HSDT | -20.7% ROA vs MBOT's -34.4%, ROIC -10.8% vs -6.2% |
HSDT vs MBOT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
HSDT vs MBOT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHSDTLAGGINGMBOT
MBOTMicrobot Medical Inc.
2leads
HSDTSolana Company
2leads
6 Total Categories
CATEGORYLEADERvs MBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HSDT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HSDT6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MBOT6/6
Risk & VolatilityBeta, volatility, and downside exposure
MBOT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HSDT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
HSDT and MBOT operate at a comparable scale, with $6M and $0 in trailing revenue.
| Metric | HSDTSolana Company | MBOTMicrobot Medical … |
|---|---|---|
| RevenueTrailing 12 months | $6M | $0 |
| EBITDAEarnings before interest/tax | -$21M | -$14M |
| Net IncomeAfter-tax profit | -$41M | -$13M |
| Free Cash FlowCash after capex | -$17M | -$11M |
| Gross MarginGross profit ÷ Revenue | +91.7% | — |
| Operating MarginEBIT ÷ Revenue | -3.5% | — |
| Net MarginNet income ÷ Revenue | -6.8% | — |
| FCF MarginFCF ÷ Revenue | -2.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +33.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +3.9% | +62.8% |
HSDT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — HSDT and MBOT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | HSDTSolana Company | MBOTMicrobot Medical … |
|---|---|---|
| Market CapShares × price | $87M | $143M |
| Enterprise ValueMkt cap + debt − cash | $79M | $140M |
| Trailing P/EPrice ÷ TTM EPS | -1.16x | -2.92x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 14.40x | — |
| Price / BookPrice ÷ Book value/share | 0.16x | 9.44x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — HSDT and MBOT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
HSDT leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
MBOT delivers a -37.1% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-105 for HSDT. On the Piotroski fundamental quality scale (0–9), HSDT scores 4/9 vs MBOT's 3/9, reflecting mixed financial health.
| Metric | HSDTSolana Company | MBOTMicrobot Medical … |
|---|---|---|
| ROE (TTM)Return on equity | -105.0% | -37.1% |
| ROA (TTM)Return on assets | -20.7% | -34.4% |
| ROICReturn on invested capital | -10.8% | -6.2% |
| ROCEReturn on capital employed | -14.0% | -2.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$7M | -$3M |
| Cash & Equiv.Liquid assets | $7M | $3M |
| Total DebtShort + long-term debt | $0 | $111,000 |
| Interest CoverageEBIT ÷ Interest expense | -63.39x | — |
HSDT leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MBOT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MBOT five years ago would be worth $3,030 today (with dividends reinvested), compared to $0 for HSDT. Over the past 12 months, MBOT leads with a -15.1% total return vs HSDT's -99.0%. The 3-year compound annual growth rate (CAGR) favors MBOT at 22.8% vs HSDT's -92.9% — a key indicator of consistent wealth creation.
| Metric | HSDTSolana Company | MBOTMicrobot Medical … |
|---|---|---|
| YTD ReturnYear-to-date | -30.4% | +0.9% |
| 1-Year ReturnPast 12 months | -99.0% | -15.1% |
| 3-Year ReturnCumulative with dividends | -100.0% | +85.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -69.7% |
| 10-Year ReturnCumulative with dividends | -100.0% | -99.4% |
| CAGR (3Y)Annualised 3-year return | -92.9% | +22.8% |
MBOT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MBOT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MBOT is the less volatile stock with a 1.85 beta — it tends to amplify market swings less than HSDT's 2.77 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MBOT currently trades 45.6% from its 52-week high vs HSDT's 0.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HSDTSolana Company | MBOTMicrobot Medical … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.77x | 1.85x |
| 52-Week HighHighest price in past year | $258.50 | $4.67 |
| 52-Week LowLowest price in past year | $1.61 | $1.60 |
| % of 52W HighCurrent price vs 52-week peak | +0.8% | +45.6% |
| RSI (14)Momentum oscillator 0–100 | 58.6 | 46.3 |
| Avg Volume (50D)Average daily shares traded | 306K | 1.5M |
MBOT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | HSDTSolana Company | MBOTMicrobot Medical … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $5.50 |
| # AnalystsCovering analysts | — | 3 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HSDT leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MBOT leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallSolana Company (HSDT)Leads 2 of 6 categories
Loading custom metrics...
HSDT vs MBOT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is HSDT or MBOT a better buy right now?
Analysts rate Microbot Medical Inc.
(MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HSDT or MBOT?
Over the past 5 years, Microbot Medical Inc.
(MBOT) delivered a total return of -69. 7%, compared to -100. 0% for Solana Company (HSDT). Over 10 years, the gap is even starker: MBOT returned -99. 4% versus HSDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HSDT or MBOT?
By beta (market sensitivity over 5 years), Microbot Medical Inc.
(MBOT) is the lower-risk stock at 1. 85β versus Solana Company's 2. 77β — meaning HSDT is approximately 49% more volatile than MBOT relative to the S&P 500.
04Which is growing faster — HSDT or MBOT?
On earnings-per-share growth, the picture is similar: Solana Company grew EPS 57.
3% year-over-year, compared to 30. 5% for Microbot Medical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HSDT or MBOT?
Microbot Medical Inc.
(MBOT) is the more profitable company, earning 0. 0% net margin versus -679. 6% for Solana Company — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBOT leads at 0. 0% versus -351. 0% for HSDT. At the gross margin level — before operating expenses — HSDT leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — HSDT or MBOT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is HSDT or MBOT better for a retirement portfolio?
For long-horizon retirement investors, Microbot Medical Inc.
(MBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Solana Company (HSDT) carries a higher beta of 2. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MBOT: -99. 4%, HSDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HSDT and MBOT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: HSDT is a small-cap high-growth stock; MBOT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.